Gossamer unravels
The group's pulmonary arterial hypertension therapy might work in sicker patients, but investors are unwilling to stick around.
Gossamer could put pressure on Merck
The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.
AHA 2022 – Idorsia and Cincor move forward in hypertension
Aprocitentan’s effect size falls short of expectations, raising the risk that J&J might cool on its Idorsia partnership, while Cincor remains one to watch.
AHA 2022 – History repeats for Medtronic
The company’s renal denervation system has failed in a crucial late-stage trial, just as an earlier version did eight years ago.
AHA 2022 – Amgen looks good in metabolic disease
With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.
J&J enlivens the medtech merger scene
Buying Abiomed for $17bn sharpens the group’s focus, somewhat unexpectedly, on cardiovascular tech.
